Compounds > mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin
Page last updated: 2024-09-04

mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin and cyclosporine

mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin has been researched along with cyclosporine in 1 studies

Compound Research Comparison

Studies
(mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin)		Trials
(mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin)		Recent Studies (post-2010)
(mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin)		Studies
(cyclosporine)		Trials
(cyclosporine)		Recent Studies (post-2010) (cyclosporine)
6904230,5473,8026,558

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Agrawal, S; Dixit, A; Patel, DK; Singh, A; Singh, D; Singh, MP; Tripathi, P1

Other Studies

1 other study(ies) available for mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin and cyclosporine

ArticleYear
Cyclosporine A and MnTMPyP Alleviate α-Synuclein Expression and Aggregation in Cypermethrin-Induced Parkinsonism.
    Molecular neurobiology, 2015, Volume: 52, Issue:3

    Topics: alpha-Synuclein; Animals; Corpus Striatum; Cyclosporine; Dopaminergic Neurons; Metalloporphyrins; Mitochondria; Oxidative Stress; Parkinson Disease; Parkinsonian Disorders; Pyrethrins; Rats, Wistar; Substantia Nigra

2015